Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...

Emergen Research Logo The increasing prevalence of liver diseases worldwide is a major growth driver in the liver disease therapeutics mark ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

Discover how circulating cell-free DNA (cfDNA) is transforming the diagnosis and monitoring of metabolic diseases like ...

Glaucoma is a serious eye disease that gradually damages the optic nerve, leading to vision loss and, if left untreated, blindness.

"A higher FT3/FT4 ratio was associated with an increased risk of developing NAFLD (OR 1.45) and greater severity of liver fibrosis (ORs 3.21–10.80), highlighting the potential role of thyroid hormones ...